P atients on hemodialysis (HD) therapy are known to have carnitine deficiency, 1,2 which might contribute to clinical disorders (eg, cachexia, dyslipidemia, erythropoiesis-stimulating agent [ESA]-resistant anemia, insulin resistance and glucose intolerance, muscle weakness, and myopathy), as well as to intradialytic symptoms (eg, muscle cramps, hypotension, and cardiac arrhythmia). 3, 4 There have also been reports of improvement in cardiac dysfunction following levocarnitine therapy, particularly in patients with lowered cardiac systolic function or symptoms of heart failure. 5, 6 However, in individuals with normal myocardial function, one study found carnitine therapy to be beneficial, whereas another observed no benefits. 7, 8 However, these previous studies were small or not well controlled; therefore, their results are controversial. Hence, in the present study, we investigated the effects of 12 months of levocarnitine therapy on cardiac morphology and function among patients undergoing HD.
METHODS

Patients and Study Protocol
This prospective, open-label, randomized, parallel, controlled, multicenter trial screened 346 patients, of whom 222 HD patients were randomly assigned to a levocarnitine therapy group or a control group. Patients in the levocarnitine group received oral levocarnitine (Otsuka Pharmaceutical Co, Ltd) at a dose of 20 mg/ kg/d, and those in the control group received usual care (no levocarnitine therapy). Patients were monitored for 12 months. An independent investigator with no knowledge of the participants before commencement of the trial monitored the randomization of participant entry order. Dynamic balancing randomization was carried out based on age, sex, HD vintage, hemoglobin level, and presence or absence of diabetes mellitus. Thus, we ensured that there were no significant differences in baseline characteristics between groups. Details of the assignment were then given to 6 independent investigators. The study protocol was designed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Keiai Hospital, and all patients provided written informed consent. All patients were treated with HD or hemodiafiltration therapy 3 times per week in 4-hour sessions at 3 Japanese blood purification centers. This prospective study was conducted from June 2012 through December 2014.
Enrollment criteria for the study were as follows: (1) aged 20 years or older and 85 years or younger, (2) HD duration therapy longer than 6 months at enrollment, and (3) free carnitine plasma concentration , 40 mmol/L. Exclusion criteria were as follows: (1) aged younger than 20 years or older than 85 years; (2) history of severe heart failure, angina, myocardial infarction, or stroke within the past 6 months; (3) presence of infectious disease, thyroid disease, malignant tumors, or treatment with steroids or immunosuppressants; (4) current hospitalization; (5) atrial fibrillation; and (6) levocarnitine therapy or supplementation within the past 6 months. During the study period, patients continued their regular medications, such as antihypertensive agents, ESAs, phosphate binders, and lipid-lowering agents. Patients were regularly given dietary guidance by a dietician, especially those under dietary restrictions such as salt and protein intake.
Patient withdrawal from the study was considered if intolerance to levocarnitine appeared during the study and in case of medical events that resulted in death, hospitalization, or significant disability or incapacity; transfer to other hospitals; or inability to measure ejection fraction (EF) and left ventricular mass index (LVMI) by echocardiography due to poor visualization, local left ventricular wall thinning, local ventricular asynergy, or EF $ 70% at baseline.
Study Evaluations
The primary efficacy end point was the comparison of cardiac function between the 2 groups, as measured by the magnitude of change from baseline in EF evaluated by echocardiography. Secondary end points were the magnitude of changes from baseline in LVMI and clinical parameters in the levocarnitine group and a comparison to those in the control group at the end of the study. For exploratory end points, we compared levocarnitine subgroups of patients with left ventricular hypertrophy (LVH) with those without LVH.
Serum carnitine levels were determined by enzyme cycling methods as described previously. 9 Blood samples were obtained before the start of an HD session. All patients received the same ESA, namely, recombinant human erythropoietin (epoetin alfa).
The erythropoietin responsiveness index (ERI) was defined as average weekly units of ESA divided by clinical dry weight (in kg) and average blood hemoglobin (in g/dL) as described previously, 10 to normalize the amount of required ESA to the severity of anemia. These variables were evaluated at baseline and 12 months (at the end of the study). N-terminal pro2brain natriuretic peptide (NTproBNP) was measured by the electrochemiluminescence immunoassay method.
The safety and tolerability of levocarnitine treatment were assessed by monitoring and recording all adverse events, as well as monitoring clinical laboratory test results and physical assessment findings. Adherence to oral levocarnitine treatment was evaluated based on a pill count once every 2 weeks.
Assessment of Cardiac Function
Echocardiography was conducted immediately after the midweek HD session to minimize any influence of the patient's hydration state both at the beginning and end of the study. Echocardiography was performed using Vivid T7 (GE Healthcare). The echotracings were collected by 2-dimensional guided M-mode echocardiography, according to a widely accepted method.
11 All patients were examined by a single trained cardiologist, who was blinded to the documentation of participants' clinical characteristics; examinations were conducted at baseline and after 6 and 12 months of oral levocarnitine treatment (or equivalent times for the control group). For each participant, left ventricular end-diastolic dimension (LVDd), interventricular septal end-diastolic thickness (IVS), left ventricular posterior wall end-diastolic thickness (PW), left atrial dilation, and EF were measured. The normal range of LVDd was defined as 42 to 59 mm for men and 39 to 53 mm for women. 10 The ratio of early (E) to late (A) mitral valve flow velocity (E/A ratio) and the ratio of E to early tissue Doppler lengthening velocity (e 0 ) (E/e 0 ratio) were measured as the indexes of diastolic left ventricular dysfunction. 12, 13 Left ventricular mass (LVM) was calculated using Devereux's method 11 : LVM (g) 5 0. 8 
Statistical Analysis
Data were expressed as mean 6 standard deviation or median and interquartile range as appropriate. Continuous variables were compared using t test or Mann-Whitney U test, and categorical variables were compared by c 2 or Fisher exact test as appropriate to the data distribution. Changes in cardiac parameters by echocardiography, such as in EF (DEF) and LVMI (DLVMI), were defined as the differences between values at baseline and those at months 6 and 12. Those values were expressed as mean (95% confidence interval [CI] ). Differences in echocardiographic parameters between the 2 groups from baseline to 6 and 12 months were analyzed by logistic regression. In order to identify which patients within the levocarnitine group showed a favorable response to the therapy, patients with LVH were compared with those without LVH in a levocarnitine subgroup analysis. Sample size was determined based on 80% power, assuming an effect size of a 5.2% difference in change in EF from baseline between groups with a standard deviation of 11.1%, based on a previous similar levocarnitine trial. [14] [15] [16] This yielded a 2-sided significance level of 0.05 and an estimated number of evaluable patients of 146 (73 per group). We allowed for a dropout rate of 35% after randomization. Thus, a sample size of 220 randomly assigned individuals (110 per group) was necessary for this study. Statistical significance was set at P , 0.05. All analyses were performed using JMP, version 12, software (SAS Institute Inc).
RESULTS
Baseline Demographic and Clinical Data
Two hundred twenty-two eligible patients were enrolled in this trial and randomly allocated to the levocarnitine group (n 5 110) or the control group (n 5 112). Overall, 74 patients did not complete the assessment or treatment, including 35 in the levocarnitine group (32%) and 39 in the control group (35%). The other 75 patients in the levocarnitine group and 73 patients in the control group were included in the final analysis (Fig 1) . There were no significant differences in baseline demographic, hemodynamic, or anthropometric variables; dialysis mode; types of vascular access; cardiovascular comorbid conditions; or medications between groups ( Table 1 ). As shown in Table 2 , there were no significant differences in baseline characteristics of patients who were not included in the final analysis (withdrawn, dropped out, or other reasons).
During the study period, angiotensin receptor blocker treatment was interrupted in 2 patients, angiotensin receptor blocker dose was reduced in 4 patients, and calcium channel blocker dose was reduced in 4 patients in the levocarnitine group. In the control group, angiotensin receptor blocker treatment was initiated and interrupted in 2 patients each, while calcium channel blocker dose was increased in 4 patients and reduced in 2 others. During the study period, 3 and 5 patients took the b-blocker carvedilol in the levocarnitine and control groups, respectively. Although amezinium metilsulfate, droxidopa, and midodrine were used for treating disdialysis syndrome or dialysis hypotension in both groups, the number of patients receiving these drugs showed no significant difference between the 2 groups. None of the patients received digitalis.
Effects of Levocarnitine Treatment on Cardiac Parameters
There was no significant difference in EF values at baseline between the 2 groups. As shown in Fig 2A, in the levocarnitine group, EFs were significantly increased from 53.1% 6 5.3% at baseline to 55.5% 6 5.8% at 6 months and 58.6% 6 5.5% at 12 months (both P , 0.001), while the control group showed no change in EF (53.6% 6 6.0% to 53.5% 6 5.7% at 6 months and 53.5% 6 6.2% at 12 months). EFs in the levocarnitine group were significantly higher than those in the control group at 6 (P 5 0.03) and 12 (P , 0.001) months. As shown in Fig 2B , the between-group difference (levocarnitine vs control) in mean DEF at 6 months was 2.50% (95% CI, 1.44%-3.56%; P , 0.001), and that at 12 months was 5.57% (95% CI, 4.48%-6.66%; P , 0.001).
As shown in Table 3 , LVMI decreased significantly in the levocarnitine group from 112 6 26 g/m 2 at baseline to 107 6 24 g/m 2 at 6 months (P , 0.001) and 104 6 23 g/m 2 at 12 months (P , 0.001), whereas the control group showed no change in LVMI. Furthermore, a significant difference was noted in LVMI between the 2 groups at 12 months (P 5 0.04). As shown in Table 4 , the difference between groups in mean DLVMI at 6 months was 5.99 (95% CI, 2.61-9.37) g/m 2 (P , 0.001) and that at 12 months was 10.50 (95% CI, 7.51-13.60) g/m 2 (P , 0.001). Additionally, we tested for an interaction between baseline LVMI differences and change in EF, and a significant interaction was observed (P 5 0.01).
Systolic and diastolic blood pressures and heart rate did not change significantly in either group over the 12-month study period. NT-proBNP levels were significantly decreased in the levocarnitine group throughout the study. However, no such effect was observed in the control group. Other cardiac parameters measured by echocardiography at baseline showed no significant differences between the 2 groups. Although LVDd in the levocarnitine group did not change significantly, it showed a significant increase in the control group at 12 months (P 5 0.002), and a significant difference was noted in the comparison of DLVDd between the control and levocarnitine groups (P 5 0.001). Although left atrial dilation and E/A ratio showed no significant differences in the 2 groups, a significant difference was observed for DE/e 0 ratio at 12 months between the 2 groups (P 5 0.03). Table 5 shows clinical variables of patients who completed the trial at baseline and at the end of the study in the 2 groups. There were no significant differences in serum urea nitrogen, albumin, electrolyte, lipid profile, or C-reactive protein values between the levocarnitine and control groups at baseline. Furthermore, there were no significant changes in those values within groups or between the 2 groups at 12 months. Although there was no significant change in hemoglobin concentrations within groups or between the levocarnitine and control groups at 12 months, a significant reduction in ERI was noted in the levocarnitine group. At 12 months, transferrin saturation and serum ferritin values were significantly decreased in both groups. In the levocarnitine group, total, free, and acylcarnitine levels were significantly increased at 12 months, whereas the acyl to free carnitine ratio decreased significantly and was lower than that in the control group. 
Effects of Levocarnitine Treatment on Clinical Variables
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Subgroup Analysis With or Without LVH in Levocarnitine Group
Subgroup analysis was performed for patients in the levocarnitine group with (n 5 52) or without (n 5 23) LVH at baseline. As shown in Fig 3A, EF in the LVH group increased significantly, from 52.3% 6 5.4% at baseline to 56.0% 6 6.1% at 6 months (P , 0.001) and to 59.6% 6 5.0% at 12 months (P , 0.001), while there was no significant effect on EF in the group of patients without LVH. At 12 months, a significant difference was observed in EF when comparing the groups with and without LVH (P 5 0.003). As shown in Fig 3B, the between-group difference in mean DEF at 6 months was 2.67% (95% CI, 0.99%-4.49%; P 5 0.005); at 12 months, it was 5.96% (95% CI, 4.95%-6.96%; P , 0.001). LVMI in the LVH group decreased significantly, from 125.2 6 21.6 g/m 2 at baseline to 112.1 6 22.1 g/m 2 at 6 months and 107.8 6 21.9 g/m 2 at 12 months (both P , 0.001), while the group of patients without LVH showed no change in LVMI (85.1 6 13.1 g/m 2 at baseline, 88.1 6 12.6 g/m 2 at 6 months, and 87.7 6 17.3 g/m 2 at 12 months). As shown in Fig 3C, the between-group difference in mean DLVMI at 6 months was 216.0 (95% CI, 223.6 to 28.5) g/m 2 (P , 0.001); at 12 months, it was 220.0 (95% CI, 228.3 to 211.7) g/m 2 (P , 0.001). Furthermore, E/e 0 ratio in the LVH group decreased significantly from 16.8 6 7.3 to 15.2 6 5.0 at 12 months (P 5 0.04), but no significant change was noted in the group of patients without LVH.
Tolerability
Overall, levocarnitine treatment was well tolerated. Average treatment adherence was 96.5% in the levocarnitine group, and there were no instances when this rate decreased to ,75%. During treatment, 3 patients in the levocarnitine group were excluded from the study because of adverse reactions, which included fish-odor syndrome (n 5 2) and gastrointestinal intolerance (n 5 1); these were suspected to be associated with levocarnitine treatment. Seven deaths occurred during the study period, but they were not considered to be related to levocarnitine treatment.
DISCUSSION
It has been reported that serum free carnitine concentration is positively associated with EF; in a study of 16 HD patients, EF increased from 42.4% to 48.6% after 3 months of carnitine therapy. 5 There have also been a few reports involving small numbers of patients indicating that levocarnitine therapy significantly decreases LVMI and cardiothoracic ratio, while increasing EF. [6] [7] [8] 14 Levocarnitine administration has been reported to improve endothelial dysfunction, ameliorate cardiac dysfunction, and lower hospitalization rates in patients receiving HD. 17, 18 In the present 12-month study of patients undergoing HD, levocarnitine therapy increased the free carnitine concentration, decreased the acyl to free carnitine ratio, and increased EF, especially in patients with LVH, defined as LVMI . 102 g/m 2 for men and . 88 g/m 2 for women at baseline. Using results of the subgroup analysis stratified by LVH status, we retrospectively calculated the power of the test as 83%, with a 2-sided significance level of 0.05. Nevertheless, a further large-scale study would be needed to clarify the characteristics of responders to levocarnitine treatment because the sample size of the present study was small.
LVH is a common clinical entity; furthermore, it independently predicts cardiac death in patients receiving dialysis. 19, 20 Although largely thought to stem from hemodynamic overload caused by arterial hypertension, uremic anemia, extracellular fluid volume expansion, and arteriovenous fistula formation in patients with HD, many patients with chronic kidney disease already have LVH before the initiation of HD therapy. Other mechanisms might play a role in the genesis of LVH, such as the participation of fibroblast growth factor 23. 21, 22 LVMI, which is a suitable measure of LVH even for patients receiving long-term HD, 8 increases because of the corresponding hemodynamic overload and also from remodeling to make up for reduced myocardial contractility. In HD patients, the degree of LVH correlates with the severity of left ventricular dilation, as well as with contractile myocardial failure. 23 Therefore, a decrease in LVMI due to levocarnitine therapy might have led to the decrease in LVDd observed in the present study. Levocarnitine therapy may lead to higher water excretion by improved blood pressure stability during HD treatment; this may result in reduced LVH and increased EF. However, in the present study, we could not assess the exact changes in total and intravascular body water following levocarnitine therapy. Therefore, to clarify the manner in which levocarnitine affects changes in body water and lean body mass, a further study using bioelectrical impedance analysis would be useful.
In 2003, with increasing evidence from basic science and clinical data from small studies, a consensus conference organized by the National Kidney Foundation issued recommendations for using levocarnitine in dialysis-related carnitine deficiency.
24
Although it was suggested that the clinical response to levocarnitine be evaluated at 3-month intervals, in the present study, we found that 6 months of levocarnitine therapy was needed to improve cardiac function. It is possible that in patients with preserved EF, a relatively long duration of therapy may be needed for discernible improvement. In a rat model, levocarnitine administration has been reported to prevent the development of heart failure, with preserved EF and improved survival through the attenuation of left ventricular fibrosis and stiffening. 25 These results suggest that levocarnitine therapy may improve not only contractility, but also diastolic failure. Although we observed that EF and LVMI improved after 6 months of therapy, E/e 0 ratio, which indicates diastolic failure, improved only after 12 months of levocarnitine treatment. Therefore, a relatively long duration of levocarnitine therapy is expected to be necessary for improvements in diastolic failure.
Levocarnitine administration enhances the response to ESAs in patients receiving HD by increasing hemoglobin levels, reducing the required ESA dose, or decreasing ERI. 26, 27 In the present study, ERI in the levocarnitine group was significantly reduced without increased hemoglobin levels. Previous studies have reported that long-term supplementation with levocarnitine improves myocardial contractility and reduces left ventricular volume, together with the amelioration of uremic anemia or improvements in uremic anemia by administration of ESAs, which reduces LVMI. 6 Although it is well known that systolic blood pressure and hemoglobin levels are the key factors influencing LVH and heart failure in patients with HD, no changes in these factors were noted in the present study. Furthermore, the improvement in EF was not associated with the change in ERI. Some of our patients had received reninangiotensin-aldosterone system inhibitors or bblockers, which induce regression of LVH. However, because both our treated and untreated groups included such patients, we consider that the observed decrease in LVMI resulted from levocarnitine therapy rather than from antihypertensive agents.
Our study has several limitations. First, measures of oxidative stress markers and arterial stiffness were unavailable. Therefore, the mechanisms underlying improved cardiac structure and function following levocarnitine therapy, such as those mediated by antioxidative or anti-inflammatory processes, are unknown. Second, this study did not measure the effect of levocarnitine therapy on global outcomes in HD patients such as mortality, morbidity, and health care costs. Finally, this study was not double blinded. Therefore, an adequately powered high-quality clinical trial, such as a prospective, double-blind, randomized, controlled trial, is necessary to clarify whether improvements in cardiac function due to levocarnitine treatment lead to improved prognosis.
The number of the patients included in the present study was relatively large compared with previous studies; nevertheless, large robust randomized controlled studies are lacking. The present study showed that levocarnitine therapy was useful for HD patients with carnitine deficiency, especially in patients with LVH. Such patients might benefit from levocarnitine therapy because of the amelioration of cardiac function and reduction of LVH. Large clinical studies are necessary to ascertain whether this therapy significantly affects cardiac mortality and morbidity in patients undergoing dialysis. 
